We summarized the existing metabolic targets used in DMARDS and highlighted several future potential targets to treat autoimmune diseases including mTOR, GCN2, IDO1, ARG 1, kynurenine, cysteine, S1P receptor and fatty acid enzymes. Here, IDO1 is linked to autoimmune disease.